A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.

CONCLUSION: Although this study did not meet its efficacy endpoints, onabotulinumtoxinA was well tolerated in this adolescent population. Given previous data demonstrating the benefits of onabotulinumtoxinA in adults with CM, additional studies with design modifications, including adequate statistical power, to assess the efficacy of multiple treatment cycles of onabotulinumtoxinA for CM prevention in adolescents may be informative. PMID: 32037549 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32037549?dopt=Abstract

Source: Headache - February 8, 2020 Category: Neurology Authors: Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF Tags: Headache Source Type: research